Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

ExpreS2ion Biotech Holding AB (EXPRS2)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.55 -0.20    -7.12%
11:23:42 - Closed. Currency in SEK ( Disclaimer )
Type:  Equity
Market:  Sweden
ISIN:  SE0008348262 
S/N:  51404958
  • Volume: 41,717
  • Bid/Ask: 2.60 / 2.60
  • Day's Range: 2.51 - 2.74
ExpreS2ion Biotech 2.55 -0.20 -7.12%

ST:EXPRS2 Financials

 
A brief overview of the ST:EXPRS2 financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of ExpreS2ion Biotech Holding AB over time.

ExpreS2ion Biotech Holding AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 1.45 million compared to SEK 0.833 million a year ago. Revenue was SEK 1.86 million compared to SEK 0.909 million a year ago. Net loss was SEK 21.83 million compared to SEK 30.7 million a year ago.For the nine months, sales was SEK 5.94 million compared to SEK 4.11 million a year ago. Revenue was SEK 6.52 million compared to SEK 4.57 million a year ago. Net loss was SEK 78.17 million compared to SEK 70.07 million a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

EXPRS2 Income Statement

Gross margin TTM 58.55%
Operating margin TTM -1,204.28%
Net Profit margin TTM -1,090.91%
Return on Investment TTM -115.91%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 2.28 2.07 2.07 2.59
Gross Profit 1.76 1.41 1.08 1.25
Operating Income -20.6 -21.38 -33.24 -29.97
Net Income -17.82 -19.82 -30.04 -26.31

EXPRS2 Balance Sheet

Quick Ratio MRQ 5.14
Current Ratio MRQ 6.03
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.45%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 74.26 74.26 115.91 103.12
Total Liabilities 13.33 13.33 15.22 23.66
Total Equity 60.93 60.93 100.69 79.47

EXPRS2 Cash Flow Statement

Cash Flow/Share TTM -1.96
Revenue/Share TTM 0.17
Operating Cash Flow  -131.63%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -14.98 -13.63 -34.11 -39.53
Cash From Investing Activities -0.019 -0.022 -0.747 -1.22
Cash From Financing Activities -2.59 0.023 47.08 0.709
Net Change in Cash -19.58 -15.35 16.33 -39
* In Millions of SEK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EXPRS2 Comments

Write your thoughts about ExpreS2ion Biotech Holding AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Emrah Gülmez
Emrah Gülmez Aug 31, 2023 11:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shit stock
hans eriksen
hans eriksen Apr 06, 2022 3:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
emi 12,50 ;-)
Dr Rich
Dr Rich Dec 17, 2021 7:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
time 2fly again
Anton Førby
Anton Førby Jul 30, 2021 5:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Best stock i have!🤑
Dennis Grønbech
Dennis Grønbech Mar 22, 2021 4:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Corona vacine test in person in holland if the tecnology is woorking maybe their breastcancer vacine can be usefull that would be crazy...
Poul Andreas Hansen
Poul Andreas Hansen Jan 11, 2021 4:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🤑
Aynaz Rostami
Aynaz Rostami Sep 09, 2020 6:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I dont understand why it Should raise?
Mads Nielsen
Mads Nielsen Jun 10, 2020 2:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-that-the-cvlp-covid-19-vaccine-shows-strong-virus-neutralization-properties-in-,c3131028
Michal Bernad
Michal Bernad May 15, 2020 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah, it looks good. But i'm not that happy about their Dividend plans :(
Mads Nielsen
Mads Nielsen May 15, 2020 6:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Currently working on a Covid-19 vaccine (in collaboration with Bavarian Nordic) + a Covid-19 Antibody test (in collaboration with Novo Nordisk). Promising progress...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email